

Supplemental table 1. Baseline characteristics of included patients.

Fibrosis stage	Normal histology	Mild fibrosis (20)			Advanced fibrosis (13)		
		HBV (1-4)	HCV (1-2)	NASH (1-2)	HBV (5-6)	HCV (3-4)	NASH (3-4)
Patients number	18	HBV (8)	HCV (9)	NASH (3)	HBV (4)	HCV (8)	NASH (1)
Age (age)	46.6±6.2	54.8±9.0	46.8±6.6	52.0±2.2	58.3±5.4	56.8±9.1	51.0
Serum TB (umol/L)	7.9±3.0	16.7±5.5	14.5±4.5	13.3±4.3	21.0±4.7	18.8±3.2	22.4
Serum ALT (U/L)	18.1±9.1	58.0±18.2	65.9±36.0	55.7±18.4	103.5±26.5	78.9±24.8	66.0
Serum AST (U/L)	23.1±10.3	64.5±22.7	57.9±26.8	45.0±8.8	80.5±7.0	76.0±33.1	78.0
Serum ALB (g/L)	41.6±1.8	39.1±1.9	40.7±2.6	39.2±1.4	35.4±2.1	34.8±2.1	35.6

Hepatic fibrosis stage in patients with HBV infection was defined as Ishak fibrosis score, 1-4 for Mild fibrosis, 5-6 for Advanced fibrosis.¹⁻⁴

Hepatic fibrosis stage in patients with HCV infection was defined as Metavir score, 1-2 for Mild fibrosis, 3-4 for Advanced fibrosis.³⁻⁵

Hepatic fibrosis stage in patients with NASH was defined as NAFLD activity score, 1-2 for Mild fibrosis, 3-4 for Advanced fibrosis.⁶⁻⁸

Quantitative variables are in mean±SD. HBV, Hepatitis B virus; HCV, Hepatitis C virus; NASH, non-alcoholic steatohepatitis; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TB, total bilirubin.

Supplemental table 2. Hepatic fibrosis stage in patients with HBV infection was defined as Ishak fibrosis score.

Fibrosis stage (Ishaks)	1	2	3	4	5	6
Patients number	3	2	2	1	1	3
Age (age)	47.3±4.0	57.5±1.5	59.5±12.5	62	65	56±4.2
Serum total bilirubin (umol/L)	10.9±3.0	16.7±3.0	22.1±0.2	23.2	23.6	20.1±5.1
Serum ALT (U/L)	44.7±19.0	61.0±6.0	62.0±11.0	84.0	121	97.7±28.2
Serum AST (U/L)	56.7±32.3	66.5±11.5	68.0±13.0	77.0	82.0	80.0±8.0
Serum albumin (g/L)	40.9±1.1	38.3±1.9	38.3±0.4	36.9	35.6	35.3±2.5

Supplemental table 3. Hepatic fibrosis stage in patients with HCV infection was defined as Metavir score

Fibrosis stage (Metavir)	1	2	3	4
Patients number	6	3	3	5
Age (age)	45.8±7.3	51.3±2.9	56.7±5.4	56.8±10.7
Serum total bilirubin (umol/L)	12.7±4.0	18.2±2.9	19.8±2.5	18.1±3.4
Serum ALT (U/L)	60.3±39.7	76.5±28.5	80.0±18.6	78.0±28.0
Serum AST (U/L)	55.8±31.8	62.0±10.0	74.0±37.0	77.2±30.4
Serum albumin (g/L)	41.6±2.6	39.1±1.4	35.7±1.7	34.2±2.1

Supplemental table 4. Hepatic fibrosis stage in patients with NASH was defined as NAFLD activity score

Fibrosis stage (NAS)	1	2	3	4
Patients number	2	1	0	1
Age (age)	51.0±2.0	54	—	51
Serum total bilirubin (umol/L)	12.3±5.0	15.5	—	22.4
Serum ALT (U/L)	53.0±22.0	61	—	66
Serum AST (U/L)	46.5±10.5	42	—	78
Serum albumin (g/L)	40.1±0.6	37.3	—	35.6

Supplemental table 5. Primers for mice genotyping

Primer name	Target	No	Lot	Direction	Sequence	wt	ko	Blast	PRI	Using	Method	Cite
TL-CRE-G-JCYK-K	Lyz2Mut	C66	1	Reverse	5'-CCCAGAAATGCCAGATTACG-3'	-	750-bp	N		Genomic DNA	Age	JYCK
		C67		Forward	5'-CTTGGGCTGCCAGAATTTCTC-3'					Tail		
TL-CRE-G-JCYK-W	Lyz2WT	C67	1	Reverse	5'-CTTGGGCTGCCAGAATTTCTC-3'	350-bp	-	Y		Genomic DNA	Age	JYCK
		C68		Forward	5'-TTACAGTCGGCCAGGCTGAC-3'					Tail		
NM-FSTL1-G-JYCK-FL	FSTL1-FLOX	FI34F-1	1	Reverse	5'-ACATGGTGACCATCCTTCGG-3'	547	734			Genomic DNA	Age	JYCK
		FI34R-1		Forward	5'TTCTAGGTTCCCTCCTAAAAC-3'					Tail		

Supplemental table 6. Primer sequences for the amplification.

Gene	Forward Primer (5' → 3')	Reverse Primer (5' → 3')
FSTL1(Human)	GCCATGACCTGTGACGGAAA	CAGCGCTGAAGTGGAGAAGA
Collagen I (Human)	GAGGGCCAAGACGAAGACATC	CAGATCACGTCATCGCACAAAC
TIMP-1 (Human)	CTTCTGCAATTCCGACCTCGT	CCCTAAGGCTTGGAACCCTTT
β-actin(Human)	CATGTACGTTGCTATCCAGGC	CTCCTTAATGTCACGCACGAT
α-SMA(Mouse)	GTCCCAGACATCAGGGAGTAA	TCGGATACTTCAGCGTCAGGA
Collagen-I (Mouse)	GCTCCTCTTAGGGGCCACT	CCACGTCTCACCATTGGGG
TIMP-1 (Mouse)	GCAACTCGGACCTGGTCATAA	CGGCCCGTGATGAGAAACT
β-actin (Mouse)	GGCTGTATTCCCCTCCATCG	CCAGTTGGTAACAATGCCATGT
TNF-α (Mouse)	GCCAGAGGGCTGATTAGAGA	CAGCCTCTTCTCCTTCCTGAT
IL-1β (Mouse)	CCAGGATGAGGACCCAAGCA	TCCCGACCATTGCTGTTTCC
IL-10 (Mouse)	ACAGGGAAGAAATCGATGACA	TGGGGGAGAACCTGAAGAC
iNOS (Mouse)	AATCTTGGAGCGAGTTGTGG	CAGGAAGTAGGTGAGGGCTTG
Argines1 (Mouse)	CTCCAAGCCAAAGTCCTTAGAG	AGGAGCTGTCATTAGGGACATC
TGF-β (Mouse)	CGCCATCTATGAGAAAACCAA	GAGTTCCACATGTTGCTCCA

References

1. Sun, Y., et al., *Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy*. Clin Gastroenterol Hepatol, 2020. **18**(11): p. 2582-2591 e6.
2. Sterling, R.K., et al., *Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults*. Hepatology, 2020. **71**(2): p. 411-421.
3. Patin, E., et al., *Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection*. Gastroenterology, 2012. **143**(5): p. 1244-1252 e12.
4. Cacoub, P., et al., *Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02*. J Hepatol, 2008. **48**(5): p. 765-73.
5. Konerman, M.A., et al., *Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfecting adults: prospective analysis of 435 liver biopsy pairs*. Hepatology, 2014. **59**(3): p. 767-75.
6. Kleiner, D.E., et al., *Design and validation of a histological scoring system for nonalcoholic fatty liver disease*. Hepatology, 2005. **41**(6): p. 1313-21.
7. Newsome, P.N., et al., *FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study*. Lancet Gastroenterol Hepatol, 2020. **5**(4): p. 362-373.
8. Harrison, S.A., et al., *NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis*.

Hepatology, 2020. **71**(4): p. 1198-1212.